Brief: WPD Pharmaceuticals Announces Amended Sublicense Agreement With Moleculin Biotech For Wp1066, Wp1122 And Annamycin Drug Candidates
30/03/2021 13:09
March 30 (Reuters) - WPD Pharmaceuticals Inc WBIO.CD :
* WPD PHARMACEUTICALS ANNOUNCES AMENDED SUBLICENSE AGREEMENT
WITH
MOLECULIN BIOTECH FOR WP1066, WP1122 AND ANNAMYCIN DRUG
CANDIDATES
* WPD PHARMA - AMENDMENT EXTENDS PERIOD OF TIME WHICH WPD
HAS TO
EXPEND RESEARCH, DEVELOPMENT AND COMMERCIALIZATION COSTS TO 8
YEARS FROM FEB, 2019
Source text for Eikon: ID:nGNX4Y7vFF
Further company coverage: WBIO.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on WPD Pharmaceuticals
See all newsBrief: Mabion Signs LoI With WPD Pharmaceuticals On Extension Of Cooperation
Brief: Mabion Signs About 2 Mln Zloty Deal With WPD Pharmaceuticals
Brief: WPD Pharmaceuticals Signs Annex To License Agreement With Wake Forest University Health Sciences
Brief: WPD Pharmaceuticals Announces Proposed Restructuring Of Polish Subsidiary
Brief: WPD Pharmaceuticals Enters Into Amended And Restated Sublicense Agreement With Moleculin Biotech